Pharma China Inaugurates Advisory Board with Nine Distinguished Leaders of the Pharma Industry in China
Pharma China is proud to announce the inauguration of its Board of Advisors.
This nine-member board is composed of some of the most distinguished leaders of the pharmaceutical industry in China and they bring with them a wealth of experience in many areas ranging from strategic planning for China, pricing and reimbursement issues, industry association/government affairs, market research, pharmaceutical sales & marketing, clinical/preclinical CRO businesses, biotech and new drug research, API sourcing, and issues relating to harmonization of mainland Chinese and Hong Kong pharmaceutical industries and markets.
Our editorial team will be greatly strengthened with valuable input from our senior advisors, and we will invite them to write for us from time to time.
Board of Advisors
Dr. Rob Bryant - Principal, Brychem Business Consulting
Peter Chua - President, Association of Hong Kong Healthcare Professionals; Member, the Pharmacy & Poisons Board of the Hong Kong Government; President, Huatai Pharmaceutical Ltd., Hong Kong; Director, Beijing United Pharmaceutical Ltd.; Justice of Peace (HK); and former President, Hong Kong Pharmaceutical Society.
Robert Pollard - Director, Synovate Healthcare China
Dr. Xiaomei Li Reckford - CEO, Quintiles Greater China
Dr. Jiaxiang Shen - Senior Fellow, Chinese Academy of Engineering; Honorary Chairman, the Pharmacy College of Tianjin University; advisor to many Chinese government agencies; and former Deputy Chief Engineer, State Pharmaceutical Administration of China and Director, National Institutes for Pharmaceutical R&D
Peter Scheuer - former Executive Director and Senior Advisor, R&D-based Pharmaceutical Association in China (RDPAC), Vice-Chairman of the China Association of Enterprises with Foreign Investment (CAEFI)
Dr. Dong Xie - Chairman and CEO, Frontier Biotechnology Ltd.
Cheryl Q. Xu - Advisor on China, Pharmaceutical Research and Manufacturers of America (PhRMA) and President, Aquila Health Consulting
Dr. Weiping Yang - Chairman and CEO, Fresenius Kabi China; and Director, RDPAC